TNF receptor superfamily member 5 (TNFRSF5)
Cd40 is a cell-surface receptor in the tumor necrosis factor receptor superfamily that plays a central role in immune regulation.
Cd40 is a cell-surface receptor in the tumor necrosis factor receptor superfamily that plays a central role in immune regulation. It is expressed on antigen-presenting cells (APCs) and is a key costimulatory molecule involved in activating adaptive immune responses. When engaged by agonists, Cd40 can promote APC maturation and enhance downstream immune signaling, making it an important target in immunotherapy research.
Biologically, Cd40 is relevant to both normal immune function and disease-associated inflammation. Because it can amplify immune activation, Cd40 has been investigated in cancer, neuroinflammation, and other immune-linked conditions. In therapeutic contexts, Cd40 agonism is being explored to strengthen antitumor immunity, although prior clinical experience has also highlighted safety concerns such as hepatotoxicity. Its role therefore sits at the intersection of immune stimulation, inflammatory signaling, and disease modulation.
Where the papers sit
9 papers from the last 6 months study TNF receptor superfamily member 5 (TNFRSF5) directly · updated from PubMed 2 Oct 2026
Study type 1 clinical trial · 3 human data · 5 preclinical
Themes no clear themes · 1 new direction
Those 9 do not share a common subject.
-
CD40-linked immune research appears alongside studies of cancer immunity, autoimmunity, inflammation, and treatment outcomes. Individual papers address myasthenia gravis therapies, tertiary lymphoid structures, cardiac repair, microbial toxin responses, ADHD-associated inflammatory proteins, and malignancy after PD-1 blockade. CD40 agonism or blockade is examined in only some studies, including KK2269 with docetaxel, anti-CD40 effects on activated CD4 T cells, and CD40-TRAF signaling in macrophage efferocytosis. The set supports no single biological direction or shared conclusion.
CD40 is a local organizer and maintainer of tumor tertiary lymphoid structures, not only an APC costimulatory target
The human-tumor and mouse non-small cell lung cancer tertiary lymphoid structure model found that mature intratumoral cDC1s use CD40 signaling together with MHC-I and MHC-II antigen presentation to maintain tertiary lymphoid structures, T follicular helper cells, germinal centers, and tumor-specific IgG 42462020Jul. This extends TNFRSF5 beyond the set’s therapeutic and disease-association roles: CD40 becomes part of the local tissue architecture that sustains organized antitumor immunity, suggesting that preserving or enhancing cDC1-centered tertiary lymphoid structures may be a distinct strategy from systemic CD40 agonism or blockade.
Papers
The 9 papers from the last 6 months that study TNF receptor superfamily member 5 (TNFRSF5) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis. Neurology · 17 Jul 2026 PMID 42467874
- Dendritic cells control tertiary lymphoid structure development and maintenance in cancer. Science (New York, N.Y.) · 16 Jul 2026 PMID 42462020
- Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. PloS one · 12 Jun 2026 PMID 42284279
- Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. Antonie van Leeuwenhoek · 2 Jun 2026 PMID 42230843
- Causal relationship between inflammatory proteins and attention deficit hyperactivity disorder: A serum-metabolites-mediated Mendelian randomization analysis. Medicine · 30 May 2026 PMID 42216364
- Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 May 2026 PMID 42148884
- CD40-TRAF2/3/5 Signaling Promotes Cardiac Repair by Mediating Macrophage Efferocytosis After Myocardial Infarction. Circulation · 7 May 2026 PMID 42093657
- Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 29 Apr 2026 PMID 42053989
- Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. Cancer science · 16 Apr 2026 PMID 41989931
By study type
Clinical trials (1)
- Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 29 Apr 2026 PMID 42053989
Human data, design not indexed (3)
- Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis. Neurology · 17 Jul 2026 PMID 42467874
- Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. Antonie van Leeuwenhoek · 2 Jun 2026 PMID 42230843
- Causal relationship between inflammatory proteins and attention deficit hyperactivity disorder: A serum-metabolites-mediated Mendelian randomization analysis. Medicine · 30 May 2026 PMID 42216364
Preclinical: animal, cell and lab studies (5)
- Dendritic cells control tertiary lymphoid structure development and maintenance in cancer. Science (New York, N.Y.) · 16 Jul 2026 PMID 42462020
- Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. PloS one · 12 Jun 2026 PMID 42284279
- Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research · 18 May 2026 PMID 42148884
- CD40-TRAF2/3/5 Signaling Promotes Cardiac Repair by Mediating Macrophage Efferocytosis After Myocardial Infarction. Circulation · 7 May 2026 PMID 42093657
- Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. Cancer science · 16 Apr 2026 PMID 41989931
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.